Femasys, Inc. FEMY 深 沪
等待开盘 03-26 09:30:00 美东时间
0.5128
0.000
-0.06%
华盛通- 最 高0.53
- 今 开0.53
- 成交量 30.56万股
- 最 低 0.5005
- 昨 收 0.5131
- 总市值 3051.26万
- 52周最高 1.29
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 0.3067
- 委 比 -66.67%
- 总股本 5950.19万
- 历史最高 13.75
- 量 比 0.63
- 振 幅 5.75%
- 历史最低 0.2479
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5
Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $1.5.
03-04 01:59
Femasys Secures American Medical Association CPT Editorial Panel Approval For Category III CPT Code Covering Use Of FemaSeed For Intratubal Insemination
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making
02-23 22:10
Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution
02-03 22:16
Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health
01-13 22:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
Femasys Receives 510(k) Clearance From FDA For FemVue Controlled Device, Diagnostic Solution For Controlled Contrast Delivery To Evaluate Fallopian Tube Status
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency--ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc.
2025-12-18 22:16
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Laidlaw & Co. Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $6.5
Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $6.5.
2025-11-20 22:44
Femasys shares are trading higher after the company announced FDA clearance to continue enrollment in the final phase of its FINALE trial for FemBloc and entered agreements to issue $12M in notes and warrants, potentially raising up to $58M.
Femasys shares are trading higher after the company announced FDA clearance to ...
2025-11-03 21:35
